

W=100 mm

Angirid MRTM

Modified Release Tablet

Trimetazidine Hydrochloride

COMPOSITION

Each modified release tablet contains Trimetazidine Hydrochloride BP 35 mg.

PHARMACOLOGY

Angirid MRTM (Trimetazidine Hydrochloride) has been proven to exert antianginal properties due to its specific metabolic mechanism of action. Indeed, Trimetazidine Hydrochloride reduces the metabolic damage caused during ischemia, by acting on a critical step in cardiac metabolism: fatty acid β -oxidation. This is made possible by selective inhibition of an enzyme of fatty acid β -oxidation: the long-chain 3-ketoacyl CoA thiolase (3-KAT). This inhibition results in reduction in fatty acid oxidation & stimulation of glucose oxidation. Thus, the coupling of glycolysis with glucose oxidation is improved, and ATP production is further increased, while the deleterious consequences of acidosis and of Ca²⁺ overload are limited.

INDICATIONS

Long-term treatment of angina pectoris.

DOSAGE & ADMINISTRATION

Route of administration : Orally.

1 tablet at mealtimes in the morning and evening.

CONTRAINDICATIONS

Trimetazidine is contraindicated in-patients with a known hypersensitivity to its components.

WARNING & PRECAUTION

Trimetazidine can cause or worsen parkinsonian symptoms (tremor, akinesia, hypertonias), which should be regularly investigated, especially in elderly patients. In doubtful cases, patients should be referred to a neurologist for appropriate investigations.

SIDE EFFECTS

Common : Dizziness, Headache, Abdominal pain, Diarrhoea, Dyspepsia, Nausea and Vomiting.

Rare : Palpitations, Extrasystoles, Tachycardia

USE IN PREGNANCY AND LACTATION

Pregnancy : Studies in animals have not demonstrated a teratogenic effect. However, in the absence of clinical data and for safety reasons, prescription should be avoided during pregnancy.

Breastfeeding : In the absence of data, breastfeeding is not recommended during treatment.

DRUG INTERACTIONS

No Drug Interactions so far have been reported. In particular, no interactions have been reported with beta-blocker, calcium antagonists, nitrates, heparin, hypolipidaemic agents or digitalis preparation.

OVERDOSE

No cases of occurrence of poisoning by trimetazidine owing to its overdose have been reported.

STORAGE

Store below 30^o C temperature & dry place, protected from light.

Keep all medicines out of reach of children.

PACKING

Each box contains 6 x 10 tablets in blister strips.

* Further information is available on request.

07 1222/02



Manufactured by:

The ACME Laboratories Ltd.

Dhulivita, Dhamrai, Dhaka, Bangladesh

For Health, Vigour and Happiness